Document Detail


Depot-medroxyprogesterone acetate (DMPA) and cancer: memorandum from a WHO meeting.
MedLine Citation:
PMID:  2945666     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
A review of all available data including those from the WHO Collaborative Study of Neoplasia and Steroid Contraceptives has shown no increased risk of cancers of the breast, endometrium, ovary or liver in women using depot-medroxyprogesterone acetate (DMPA). The issue of a causal association between DMPA use and cervical cancer is as yet unresolved and will require the accumulation of additional data. To date, in the WHO study only a small number of women have used DMPA for prolonged periods or have had a long interval since first use. Information on cancer risk in these women can only be gained by continuing the present study or by initiating additional studies focused on these specific topics.
Authors:
-
Related Documents :
3872736 - Current status of amantadine and rimantadine as anti-influenza-a agents: memorandum fro...
19309366 - Footprints of the eadv: a meeting report from the 17th congress of the european academy...
14608766 - How to make staff meetings more enjoyable and productive.
20074026 - Searching for the boundaries: unlimited expansion of ubiquitin and ubiquitin-like signa...
20683926 - Practical guidelines addressing ethical issues pertaining to the curation of human locu...
2050496 - The maternal erotic countertransference.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Bulletin of the World Health Organization     Volume:  64     ISSN:  0042-9686     ISO Abbreviation:  Bull. World Health Organ.     Publication Date:  1986  
Date Detail:
Created Date:  1986-11-24     Completed Date:  1986-11-24     Revised Date:  2010-10-26    
Medline Journal Info:
Nlm Unique ID:  7507052     Medline TA:  Bull World Health Organ     Country:  SWITZERLAND    
Other Details:
Languages:  eng     Pagination:  375-82     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Female
Humans
Medroxyprogesterone / adverse effects,  analogs & derivatives*
Medroxyprogesterone Acetate
Neoplasms / etiology*
Risk
Chemical
Reg. No./Substance:
520-85-4/Medroxyprogesterone; 71-58-9/Medroxyprogesterone Acetate
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Clinical disorders of the red cell membrane skeleton.
Next Document:  Beneficial actions of thromboxane receptor antagonism in hemorrhagic shock.